Search
Praxis Precision Medicines Inc
PRAXAdd to Watchlist
279.990USD
+6.000+2.19%
Market hours 11/03, 09:32（ET）
7.82BMarket Cap
LossP/E TTM
Praxis Precision Medicines Inc (PRAX) Stock Price Target & Forecast
Analyst Rating
Based on 21 analysts giving stock ratings to Praxis Precision Medicines Inc in the past month.
Buy
7 Strong Buy
12 Buy
1 Hold
0 Sell
1 Strong Sell
Target Price
641.429USD+124.68%
PRAX Analyst Recommendation Trends
In the current month, PRAX has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PRAX average Analyst price target in the last month is 641.429.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
7
7
7
7
7
7
7
6
12
12
10
10
9
8
8
8
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
21
21
19
19
18
17
17
16
PRAX Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Financial Forecasting
Based on analysts' estimates, PRAX EPS is projected to reach -3.775 in FY2026Q3, following reported EPS of -2.874 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-3.10
-3.51
-3.66
-3.78
-3.92
Actual
-3.49
-3.20
-2.87
--
--
Surprise
-12.45%
+8.73%
+21.49%
--
--
FAQs
What is Praxis Precision Medicines Inc's price target?
Analysts forecast that Praxis Precision Medicines Inc's price target is USD 641.43, with the highest forecast at USD 1.20K and the lowest forecast at USD 188.00.
How have Praxis Precision Medicines IncPRAX's recent earnings per share performed?
The market expectation was USD -2.87, while Praxis Precision Medicines IncPRAX's earnings per share (EPS) for the previous quarter was USD -3.20. EPS for the next quarter is expected at USD -3.78.
What is the analyst rating for Praxis Precision Medicines Inc?
Based on the ratings of Praxis Precision Medicines Inc's stock from 21 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.